AKTX Valuation
Akari Therapeutics PLC
$
1.020
- Overview
- Forecast
- Valuation
- Earnings
AKTX Relative Valuation
AKTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, AKTX is overvalued; if below, it's undervalued.
Historical Valuation
Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 93.54. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：1.05
Fair
-2.19
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Akari Therapeutics PLC. (AKTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-2.09
EV/EBIT
Akari Therapeutics PLC. (AKTX) has a current EV/EBIT of -2.09. The 5-year average EV/EBIT is -1.72. The thresholds are as follows: Strongly Undervalued below -4.21, Undervalued between -4.21 and -2.97, Fairly Valued between -0.48 and -2.97, Overvalued between -0.48 and 0.77, and Strongly Overvalued above 0.77. The current Forward EV/EBIT of -2.09 falls within the Historic Trend Line -Fairly Valued range.
0.00
PS
Akari Therapeutics PLC. (AKTX) has a current PS of 0.00. The 5-year average PS is 1.09. The thresholds are as follows: Strongly Undervalued below -5.24, Undervalued between -5.24 and -2.07, Fairly Valued between 4.25 and -2.07, Overvalued between 4.25 and 7.42, and Strongly Overvalued above 7.42. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.36
P/OCF
Akari Therapeutics PLC. (AKTX) has a current P/OCF of -2.36. The 5-year average P/OCF is -1.98. The thresholds are as follows: Strongly Undervalued below -4.89, Undervalued between -4.89 and -3.44, Fairly Valued between -0.53 and -3.44, Overvalued between -0.53 and 0.93, and Strongly Overvalued above 0.93. The current Forward P/OCF of -2.36 falls within the Historic Trend Line -Fairly Valued range.
-2.12
P/FCF
Akari Therapeutics PLC. (AKTX) has a current P/FCF of -2.12. The 5-year average P/FCF is -1.95. The thresholds are as follows: Strongly Undervalued below -5.86, Undervalued between -5.86 and -3.90, Fairly Valued between -0.00 and -3.90, Overvalued between -0.00 and 1.95, and Strongly Overvalued above 1.95. The current Forward P/FCF of -2.12 falls within the Historic Trend Line -Fairly Valued range.
Akari Therapeutics PLC (AKTX) has a current Price-to-Book (P/B) ratio of 1.39. Compared to its 3-year average P/B ratio of -10.63 , the current P/B ratio is approximately -113.11% higher. Relative to its 5-year average P/B ratio of -0.21, the current P/B ratio is about -768.96% higher. Akari Therapeutics PLC (AKTX) has a Forward Free Cash Flow (FCF) yield of approximately -33.01%. Compared to its 3-year average FCF yield of -72.49%, the current FCF yield is approximately -54.47% lower. Relative to its 5-year average FCF yield of -53.31% , the current FCF yield is about -38.08% lower.
1.39
P/B
Median3y
-10.63
Median5y
-0.21
-31.12
FCF Yield
Median3y
-72.49
Median5y
-53.31
Competitors Valuation Multiple
The average P/S ratio for AKTX's competitors is 3.96, providing a benchmark for relative valuation. Akari Therapeutics PLC Corp (AKTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of AKTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of AKTX in the past 1 year is driven by Unknown.
People Also Watch
DTST
Data Storage Corp
4.700
USD
0.00%
DARE
Dare Bioscience Inc
2.040
USD
+0.49%
SLGL
Sol Gel Technologies Ltd
15.160
USD
-0.59%
HUIZ
Huize Holding Ltd
2.670
USD
+8.98%
MTEK
Maris Tech Ltd
2.590
USD
+3.60%
ZOOZ
Zooz Power Ltd
1.850
USD
-2.63%
CMBM
Cambium Networks Corp
0.762
USD
0.00%
PMN
ProMIS Neurosciences Inc
0.695
USD
-0.71%
SWIN
Solowin Holdings Ltd
4.500
USD
-9.27%
FAQ
Is Akari Therapeutics PLC (AKTX) currently overvalued or undervalued?
Akari Therapeutics PLC (AKTX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 93.54. The fair price of Akari Therapeutics PLC (AKTX) is between to according to relative valuation methord.
What is Akari Therapeutics PLC (AKTX) fair value?
How does AKTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Akari Therapeutics PLC (AKTX) as of Aug 13 2025?
What is the current FCF Yield for Akari Therapeutics PLC (AKTX) as of Aug 13 2025?
What is the current Forward P/E ratio for Akari Therapeutics PLC (AKTX) as of Aug 13 2025?